← Eichor
Condition: Nk Lgl Leukemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Nk Lgl Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06530576A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Phase 1 · 9 location(s) · Memorial Sloan Kettering Cancer Center · NCT05010005The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia
Phase 1/Phase 2 · 1 location(s) · Hiroshima University Hospital · NCT05863234A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
Phase 1 · 2 location(s) · M.D. Anderson Cancer Center · NCT05834244Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
Phase 1/Phase 2 · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT05580601Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04033302Novel Therapeutic Approach for Human T-cell Malignancies
Phase N/A · 2 location(s) · Istituto Oncologico Veneto IRCCS · NCT06600568A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Phase 1/Phase 2 · 37 location(s) · Dren Bio · NCT05475925Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
EARLY_Phase 1 · 6 location(s) · New York Medical College · NCT03719105Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Off-the-shelf CD123 CAR-NK for R/R AML
EARLY_Phase 1 · 1 location(s) · Peking University People's Hospital · NCT06201247Universal 4SCAR7U Targeting CD7-positive Malignancies
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05995028Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT06158828To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
EARLY_Phase 1 · 1 location(s) · Hrain Biotechnology Co., Ltd. · NCT06045091Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting C
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092451Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
Phase 1/Phase 2 · 1 location(s) · Nationwide Children's Hospital · NCT05503134A Registry for People With T-cell Lymphoma
Phase N/A · 26 location(s) · Memorial Sloan Kettering Cancer Center · NCT059781413'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1 · 1 location(s) · John Reneau · NCT04848064Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell
Phase 2 · 1 location(s) · Federal Research Institute of Pediatric Hematology, Oncology · NCT07256210JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Phase 2 · 2 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06716658CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06307054Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
Phase 1/Phase 2 · 1 location(s) · University Hospital, Basel, Switzerland · NCT03300492Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML
Phase 1/Phase 2 · 1 location(s) · Belarusian Research Center for Pediatric Oncology, Hematolog · NCT05334693National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07019766Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Zhejiang University · NCT06367673
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.